GET DAILY SIGNALSWhy Is iRhythm Holdings (IRTC) Stock Down -20.85% Today?
Key Takeaways
- Shares of IRTC fell roughly 20.85%, trading near $103.05 versus a prior close of $130.19.
- The primary catalyst was the company's third-quarter 2026 earnings report, which revealed a widening GAAP loss and a sharper-than-expected slowdown in revenue growth.
- Secondary drivers included a flat year-over-year Zio AT business, guidance that leaned on newly acquired VitalConnect revenue, and a post-earnings analyst price-target cut.
- The move reflects a high-beta healthcare growth stock being re-rated as investors reassess its near-term growth trajectory.
- Traders are watching the VitalConnect integration, Zio AT recovery, and the resolution of an outstanding FDA warning letter.
- For deeper data on this name, explore Price Targets, Earnings, and Forecast pages.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Opening Summary
iRhythm Holdings, Inc. (IRTC), a digital health company known for its Zio wearable biosensors and ambulatory cardiac monitoring systems, saw its shares plunge in Thursday's session. The stock dropped roughly 20.85% to about $103.05, down from a prior close of $130.19. The selloff followed the company's third-quarter 2026 results, reported after the market closed on November 5, which paired solid adjusted profitability with a widening GAAP net loss and clear signs of slowing top-line momentum. Markets focused on the deceleration in growth and the quality of the company's guidance, overshadowing an otherwise strong adjusted earnings beat.
Earnings Results: A Beat on the Surface, a Miss Beneath It
The headline numbers told a conflicting story. Revenue rose 14.9% year over year to $221.6 million, essentially in line with Wall Street's consensus near $222.3 million. Adjusted EPS of $0.82 and adjusted EBITDA of $51.2 million both came in well above expectations. However, on a GAAP basis, the company posted a net loss of roughly $29.9 million, or $0.90 per share, versus a much smaller loss of $5.2 million a year earlier. The widening loss was driven in large part by about $49.8 million in litigation settlements tied to the Baxter patent dispute and a securities class action, items that are largely nonrecurring but represent real cash outflows that weighed on free cash flow.
Growth Slowdown and Zio AT Disruption
Investors reacted most sharply to the company's decelerating growth. The quarter ended a streak of seven consecutive quarters of 20%-plus revenue growth, as the closely watched Zio AT business was roughly flat year over year after growing more than 50% in 2025. Management attributed the softness to customers deferring onboarding ahead of the VitalConnect integration, and signaled the drag could persist for one to two quarters. The internally developed Zio MCT product also slipped, with the timeline shifting to an FDA submission in 2027 rather than a first-half 2027 launch, as resources were redirected toward the acquisition. The combination of a stalled flagship product line and a shifted product timeline undermined confidence in the near-term growth story.
Guidance Quality and Analyst Reaction
The company modestly raised full-year revenue guidance to a midpoint of $892.5 million, but the increase included roughly $16 million from the recently closed VitalConnect acquisition. On an organic basis, the implied range was flat to slightly below the prior outlook, implying fourth-quarter organic growth of only about 10% to 12%. Piper Sandler lowered its price target on IRTC to $150 from $160 while maintaining an Overweight rating, citing the temporary disruption in Zio AT. The market's reaction suggests investors viewed the guidance raise as less generous than it appeared and questioned whether the growth engine was losing momentum just as integration risk rises.
Market Context and Trading Activity
The selloff was accompanied by elevated trading activity, consistent with a post-earnings re-rating rather than a gradual drift lower. The move was idiosyncratic, driven by company-specific news, and diverged from broader healthcare and technology benchmarks. As a high-beta, richly valued growth name with a forward price-to-sales multiple well above the medical-device peer group, IRTC is particularly sensitive to any sign of slowing expansion. The decline pushed the stock through several near-term support levels and back toward the lower end of its recent trading range, with a 52-week low around $100.70 now within reach.
What Comes Next for IRTC
Looking ahead, investors will be focused on whether the Zio AT slowdown proves temporary, as management contends, or reflects a more durable competitive or integration-related headwind. The VitalConnect integration, including the rollout of the Vital Patch through an expanded sales force, will be a key execution test. Other factors to watch include the timing of FDA reinspection related to an outstanding warning letter, progress on the next-generation AI algorithm, and the company's ability to convert expanding margins into positive free cash flow. Risks remain, including integration execution, competitive pressure in the cardiac monitoring market, and potential fallout from a previously disclosed cybersecurity incident. The balance of catalysts suggests continued volatility as the market waits for evidence that growth reaccelerates.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and the symbols they trade. The bots featured in this section are those demonstrating standout performance in the present environment. Explore the Trending AI Robots section to see which automated strategies are currently gaining traction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
IRTC's RSI Oscillator dives into oversold zone
The RSI Indicator for IRTC moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for IRTC crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRTC advanced for three days, in 254 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IRTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 198 of 241 cases where IRTC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 66 cases where IRTC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRTC as a result. In 68 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for IRTC turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
IRTC moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.990) is normal, around the industry mean (4.137). IRTC has a moderately low P/E Ratio (-214.810) as compared to the industry average of (2.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.398) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. IRTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of monitoring and diagnostic solutions for detection of cardiac arrhythmias
Industry MedicalNursingServices
Advertisement